Cell-lineage-specific transcription factors are a group of regulatory proteins expressed in embryonic, differentiated, or neoplastic cells of the same lineage and represent a valuable repertoire of tissue-specific markers for the diagnosis of human tumors. Together with PAX2, PAX8 is a nephric-lineage transcription factor and is required for the establishment of renal-lineage cells and the formation of the kidney. In contrast to PAX2, little is known about the expression of PAX8 in adult kidney and renal tumors. In this study, we used immunohistochemistry to investigate the expression of PAX8 in adult human kidney and renal epithelial tumors. We report here that PAX8 was detected in renal epithelial cells in all segments of renal tubules from the proximal tubules to the renal papillae and in the parietal cells of Bowman's capsule in the adult kidney. PAX8 was also present in 98% of clear cell renal cell carcinomas (RCCs), 90% of papillary RCCs, and 95% of oncocytomas, similar to PAX2. In addition, PAX8 was found in 82% of chromophobe RCCs, 71% of sarcomatoid components of RCCs, and 100% (2/2) of renal medullary carcinomas. Overall, PAX8 was detected in 85% of metastatic renal tumors. Interestingly, expression of PAX8 was noted in some urothelial cells in the renal pelvis and ureters and B23% of urothelial carcinomas of the renal pelvis, but not in the urothelium or urothelial carcinomas of the urinary bladder; this probably underlines the different embryonic origins of urothelial cells in the upper and lower urinary tracts. As shown in this study, PAX8 is widely expressed in normal and neoplastic renal tissues. PAX8 may be a useful additional marker for renal epithelial tumors; however, its specificity and sensitivity await further investigation.
Cell-lineage-specific transcription factors have recently emerged as valuable diagnostic markers for human tumors. These proteins are expressed in limited types of embryonic tissues and are required for the growth and differentiation of these tissues into highly specialized tissues or organs. As some proteins continue to be expressed in the differentiated tissues during adult life or in the neoplastic tissues of the same cell lineage, detection of these proteins could indicate the primary site or the differentiation trait of a tumor. The well-established diagnostic markers in this category include TTF-1, 1, 2 CDX2, 3 MITF, 4 and myogenin. 5, 6 Renal cell carcinoma (RCC) is known for its predilection for vascular invasion and distant metastases. A significant number of cases present with extra-renal growth or metastasis at the time of diagnosis or after surgery. 7 On account of its diverse histologic features, metastatic RCC can be a diagnostic challenge and frequently requires ancillary tests, such as immunohistochemistry, for confirmation. 8 Many makers including cytokeratins (CK), CK7, CK20, EMA, vimentin, 9 c-kit, 10 P504S, 11 RCCmarker, 12, 13 aquaporin-1, 14 CD10, 15 and carbonic anhydrase 9 (CAIX) 16, 17 have been used in various panels with variable sensitivity and specificity.
PAX2 and PAX8, members of PAX gene family, are nephric cell-lineage transcription factors and have important functions in the renal organogenesis. 18, 19 Both are expressed in Wolffian ducts, the precursor tissues for the pronephros and the ureteric bud. 20, 21 Either PAX8 or PAX2 alone is sufficient for the formation of the pronephros and they are, therefore, likely functionally redundant. 21 PAX2 seems to be more important than PAX8 for the development of the mesonephros (second kidney) and metanephros (third and final kidney). Nevertheless, PAX8 is coexpressed with PAX2 in almost every stage of kidney development, such as in Wolffian ducts, ureteric buds, and the transformed mesenchymal tissues, during the formation of metanephros. 20, 21 The diagnostic applications of PAX2 have been studied more extensively than PAX8. It has been detected in Wilms tumors, 22 RCCs, 23, 24 and nephrogenic adenomas 25, 26 and has been used as a diagnostic marker for benign and malignant lesions of renal origin. 27 PAX8 was detected in pediatric Wilms tumors 28 and recently in nephrogenic adenomas; 29 however, there is little information available about its expression in adult normal or neoplastic renal tissues. Here, we report our findings of PAX8 expression in human adult kidney and renal epithelial tumors using immunohistochemistry.
Material and methods
One hundred and forty-three primary and 39 metastatic renal epithelial tumors were used in this study. The primary renal epithelial tumor samples were from radical nephrectomy specimens and were constructed into five-tissue microarrays with three representative 1 mm cores from each case. Conventional tissue sections from the metastatic tumors were used. Also included were 40 urothelial carcinomas of the urinary bladder in one-tissue microarray, which was created in the same fashion as for the primary renal epithelial tumors. Normal tissue controls included 40 cores of uninvolved renal parenchyma contained in the tissue microarrays as well as tissue sections from the uninvolved renal pelvic areas (N ¼ 5), ureters (N ¼ 5), and urinary bladder (N ¼ 10).
PAX8 immunohistochemical staining was performed in a Dako autostainer with rabbit anti-PAX8 polyclonal antibody (1:100) (Poteintech, Inc, Chicago, IL, USA). In brief, the paraffin-embedded tissue sections (5 mm thick) were obtained from the TMA or tissue blocks and baked overnight in the oven at 601C. The sections were de-paraffinized and dehydrated sequentially with PRO-PAR clearant (Anatech, Battle Creek, MI, USA) in a series of descending concentrations of alcohol and water. Antigen retrieval was done by steaming the sections for 40 min and cooling for 20 min in Cell marque in Trilogy with ethylenediaminetetraacetic acid (EDTA) solution. After antigen retrieval, the sections were incubated with Tris-buffered solution with Tween-20 for 5 min and then loaded to the Dakoautomated-staining system. The EnVision system (Dako) was used to visualize the primary antibody with hematoxylin counterstaining.
The sensitivity and specificity of PAX8 antibody were validated with an array of normal tissues, and only distinct nuclear staining was considered positive for PAX8. 29 A diffuse positive staining is referred to as 450% of tumor cells staining positive for PAX8; otherwise, staining was considered focally positive. For metastatic RCCs, cases with 45% of tumor cells staining for PAX8 were considered to be positive. The intensity of PAX8 staining in tumors was graded as weak (1 þ ), moderate (2 þ ), and strong (3 þ ).
Results
Expression of PAX8 in Normal Adult Kidney, Ureters, and the Urinary Bladder PAX8 staining was detected in the epithelial cells of the proximal and distal renal tubules, loops of Henle, collecting ducts, and the parietal epithelial cells of Bowman's capsule (Figure 1a and b) . The staining was always stronger in the distal tubules, parietal cells of Bowman's capsule, and collecting ducts (3 þ ) than in the proximal tubules (1 þ ), in which nonspecific cytoplasmic staining was also observed. Strong PAX8 staining (3 þ ) was detected in all layers of the lining urothelial cells in the renal papilla and in the initial portion of the renal pelvis. In the distal portion of the renal pelvis and ureters, PAX8 positive cells were gradually limited to the intermediate or basal layers of the urothelium with decreased staining intensity (2 þ ) (Figure 1c-e) . There was no PAX8 staining in the urothelium of the urinary bladder (Figure 1f ). PAX8 staining was neither detected in the podocytes, mesangial cells, endothelial cells, nor in the interstitium or lymphvascular structures of the kidney.
Expression of PAX8 in Renal Epithelial Tumors
The results of PAX8 staining in primary renal epithelial tumors are summarized in Table 1 . The cohort of primary renal tumors included 66 clear cell RCCs, which were from 41 men and 25 women with ages ranging from 37 to 86 years and a mean age of 64. The tumor sizes varied from 1. Twenty-one primary papillary RCCs were included in this study (18 males, 3 females, age range from 44 to 85 years, mean age 70 years) and the tumor size varied from 2.2 to 11.7 cm (average size 5.9 cm). Seventeen cases were type 1 papillary RCCs at either stage I or II, and nine or eight patients, There were 11 chromophobe RCCs in this study (6 male, 5 female, age range from 28 to 75 years, mean age 58 years) and the tumor sizes varied from 1 to 14 cm (mean tumor size 4.9 cm). The tumors were stage I in six patients, stage II in four patients, and stage III with lymph node metastases in one patient. Nine of 11 (82%) chromophobe RCCs were diffusely positive for PAX8 (Figure 3a and b), with moderate (2 þ ) in four and weak intensity (1 þ ) in five cases.
There were two renal medullary carcinomas in this study; one was a 31-year-old African American man with sickle cell trait and the other was a 34-year-old woman without a known history of sickle cell trait/anemia. The tumors were 10 and 5 cm, respectively, and located mainly in the renal medulla with extensive involvement of the renal cortices, renal pelvis, ureters-pelvic junctions, and hilar soft tissue. Histologically, both tumors were composed of poorly differentiated neoplastic cells in sheets, cords, or nests, with highgrade nuclear features, brisk mitotic activity, and necrosis. Both tumors were diffusively positive for PAX8 with moderate-staining intensity (2 þ ) (Figure 3e and f) .
The study of primary renal tumors also included 22 oncocytomas (16 male, 6 female, age range from 43 to 80 years, mean age 68 years) and the tumors varied from 1.5 to 10.7 cm (mean size 4.8 cm). Twenty-one of 22 (95%) oncocytomas were diffusely positive for PAX8 with strong staining (3 þ ) ( Figure  3c and d) in 15 cases and moderate staining (2 þ ) in 6 cases. The only oncocytoma negative for PAX8 was an 8-cm tumor from a 63-year-old man with unremarkable histologic features.
Expression of
The expression of PAX8 was also studied in urothelial carcinomas of the upper and lower urinary tract because of the discrepancy of its expression in the normal urothelial cells of these areas. The cases included 17, 2, and 40 urothelial carcinomas of the renal pelvis, the ureters, and the urinary bladder, respectively. The nuclear features were graded by a three-tier system. The nuclei of 10, 6, and 1 urothelial carcinomas of the renal pelvis were graded as 3, 2, and 1, respectively. The two urothelial carcinomas of the ureter were nuclear grade 3. Twenty-seven of the 40 urothelial carcinomas of the bladder were graded as nuclear grade 3 and the rest were nuclear grade 2. Diffuse and moderately strong staining (2 þ ) of PAX8 was detected in 4 (B23%) of the 17 urothelial carcinomas of the renal pelvis (Figure 4) , including three cases with nuclear grade 2 and one case with nuclear grade 3. There was no PAX8 detected in the 2 urothelial carcinoma of the ureters or the 40 urothelial carcinomas of the urinary bladder. The results are also summarized in Table 1 .
Expression of PAX8 in Metastatic RCCs
Of the 39 metastatic RCCs, 5 were in regional lymph nodes, 6 in lung, 4 in liver, 7 in bone or soft tissue, 5 in brain, 5 in adrenal glands, 6 in pancreas, and 1 in thyroid. Of these, 32 were clear cell type, 3 papillary, 2 poorly differentiated, 1 displayed rhabdoid features, and 1 had a spindle cell component. PAX8 was detected in 33 (85%) of 39 metastatic RCCs, with weak staining (1 þ ) in 11, moderate staining (2 þ ) in 17, and strong straining (3 þ ) in 5 cases. Five of the clear cell types and the tumor with rhabdoid features were negative for PAX8. The spindle cell RCC was weakly positive for PAX8, whereas the two poorly differentiated metastatic RCCs were moderately positive. The results are summarized in Table 2 . There was no PAX8 staining in the parenchyma of the lung, liver, PAX8 expression in normal and neoplastic renal tissues G-X Tong et al adrenal tissues, or pancreas. Some lymphocytes did stain positive for PAX8; however, they are morphologically distinct from the metastatic carcinoma and will not cause diagnostic difficulties.
Discussion
PAX8 and PAX2 are important developmental transcription factors in renal organogenesis. 18, 19, 30 Expression of PAX8 in the anlagen tissues for the future kidney occurs slightly earlier than PAX2. Thereafter, both PAX8 and PAX2 have similar expression patterns in the course of kidney formation. Either PAX8 or PAX2 is necessary and sufficient for the establishment of nephric-lineage cells and the formation of first embryonic kidneys, the pronephros. 30 After the formation of the pronephros, PAX2 seemingly has more important functions in the continuation of kidney development 
PAX8 expression in normal and neoplastic renal tissues G-X Tong et al
and eventual formation of metanephros. Absence or malformation of kidney is associated with PAX2 mutation alone, whereas mice with PAX8 deletions have normal kidneys. 18, 19 However, the additional mutation of PAX8 would exacerbate the kidney defects caused by PAX2 mutation. 21 It has been reported that PAX8 expression is decreased or absent in mature mice kidneys; however, its expression and cellular distribution in adult human kidneys are largely unknown. 28 We showed here by immunohistochemistry that PAX8 is expressed in adult human kidney epithelial cells of the proximal and distal convoluted tubules, loops of Henle, collecting ducts, and the parietal cells of Bowman's capsule, with lower levels of expression in the proximal renal tubules than in other segments. PAX8 expression was not detected in mesangial cells, endothelial cells, and visceral cells of Bowman's capsules in the glomeruli. No PAX8 staining was detected in the stroma or renal vasculature. The PAX8 expression in normal and neoplastic renal tissues G-X Tong et al functions of PAX8 in adult kidneys have not been elucidated, but it is probably involved in maintaining the differentiated features and specialized functions of renal epithelial cells. 21, 31 Renal epithelial cells differ in their embryonic origins. 32 The ureteric bud gives rise to the collecting duct system by dichotomous branching. The principal cells of the collecting duct are epithelial in origin and are the direct progenies of the epithelial cells of the ureteric bud. 33 However, the tubular cells proximal to the loop of Henle (the so-called 'proximal nephron') are derived from the mesenchymal cells surrounding the branching tips of the ureteric bud. The mesenchymal cells are transformed into epithelial cells and form the proximal portion of the nephron from the proximal tubules to the loops of Henle. The mesenchymal-epithelial transformation is mediated by mutual induction between the mesenchymal cells and the branching ureteric bud. 33 The differences in embryonic origins and functions in the different segments of nephron may have contributed to the diversity of morphologic patterns, molecular, and immunohistochemical phenotypes of common renal epithelial tumors. 34 On account of these variable features and the absence of renal-specific positive markers, 13 a panel of immunohistochemical markers is always required to substantiate the diagnosis and classification of renal epithelial tumors. Therefore, renal-specific immunohistochemical markers are of great diagnostic interest.
Renal epithelial tumors, especially clear cell RCCs, are typical for the coexpression of both epithelial and mesenchymal differentiation markers, CK, and vimentin, which are always included in the differential immunohistochemistry panels. Coexpression of CK and vimentin may be a reflection of mesenchymal origin of the proximal renal epithelial cells from which most common renal epithelial tumors are purportedly derived. 35 Additional markers, such as CK7, CK20, EMA, CD10, c-kit, and CAIX, have been used for the diagnosis and classification of renal epithelial tumors. However, the specificity and sensitivity of these markers are limited because the expression of these markers is not limited to the renal tissues and there is significant overlapping with tumors of other tissue origins.
9-11,15-17 RCC-marker 12,13 and aquaporin-1 14 are the markers with relative high specificity to the renal tissue, which have improved the diagnostic specificity and sensitivity of renal epithelial tumors by immunohistochemistry. However, these markers have some intrinsic limitations. As they are usually the terminal differentiation products of renal epithelial cells, they appear in the late stages of development and on the cell surface of the fully PAX8 expression in normal and neoplastic renal tissues G-X Tong et al differentiated cells, and they are usually less detectable in poorly differentiated malignant tumors. In addition, most of these proteins were later found not to be as specific as initially claimed. [12] [13] [14] In contrast, the cell-lineage-specific transcription factors are expressed much earlier during the development and most of them are the 'initiators' of specific cellular differentiation. They appear before the terminal differentiation proteins and are more frequently detected in poorly differentiated tumors. Expression of these transcription factors is usually limited to normal and neoplastic tissues of the same cellular lineages. In addition, these proteins have distinct nuclear staining, which makes the interpretation of immunohistochemistry staining more reliable and more appealing as a resource for the identification of tissue-specific immunohistochemistry markers. The specificities have been upheld for most transcription factors in use. [1] [2] [3] [4] [5] [6] PAX2 is the first renal-specific transcription factor whose diagnostic application in renal epithelial tumors has been investigated extensively. [22] [23] [24] 27 The distribution pattern of PAX8 showed in this study indicates that it may be used as a pan-renalepithelial marker, in addition to its functional counterpart PAX2.
PAX2 was shown in 84-93% of clear cell RCCs, 85-100% of papillary RCCs, and 87% of oncocytomas. 23, 24, 36 We show here that 98% of clear cell RCCs, 90% of papillary RCCs, and 95% of oncocytomas were positive for PAX8, frequencies which are similar or better than for PAX2. PAX8 was also detected in 85% of metastatic RCCs in this study. In addition, PAX8 was detected in 82% of chromophobe RCCs, 100% of renal medullary carcinomas, and 71% of sarcomatoid component of RCC, which are usually negative for PAX2, aquaporin-1, and CAIX. This suggests that PAX8 has a broader diagnostic application than these markers. For example, detection of PAX8 in a poorly differentiated carcinoma of the kidney would help to establish the diagnosis of rare and high-grade primary renal tumor, such as renal medullary or collecting duct carcinomas.
We also observed a differential expression pattern of PAX8 in the urothelium of upper and lower urinary tract. PAX8 was detected in the full thickness of the urothelium in the renal papillae. PAX8 positive cells decreased in number in the renal pelvis, ureters, and were gradually confined to the intermediate and basal layers. No PAX8 was detected in the urothelium of the urinary bladder or urethra. This expression pattern may reflect the different embryonic origins of the urothelium of the upper and lower urinary tracts. As for the collecting ducts, the renal pelvis and ureters are also derived from the ureteric bud. 32 When the proximal portion of the ureteric buds gives rise to the collecting duct system by dichotomous branching, its distal portion distends and elongates to form the renal pelvis. While extending distally, the ureteric bud acquires smooth muscle and connective tissues to form the tubular ureters. At the same time, the epithelial cells of the ureteric bud undergo morphologic and functional transformation from a single layer of cuboidal cells to the urothelium consisting of multiple layers of cells at different differentiation stages to cover the inner surface of the renal pelvis and ureters. Therefore, it is not surprising to observe expression of PAX8 in the proximal portion of the upper urinary tract and in some (B23%) of urothelial carcinomas of the renal pelvis. The cells at the basal layer of the ureteral epithelium may represent the less differentiated cells, which still maintain some features of the epithelial cells in the ureteric bud including expression of PAX8 as observed in our study. The decreased PAX8 expression distally along the upper urinary tract might be the result of interaction of the epithelial cells with the surrounding smooth muscle cells, and the consequence of metaplastic changes of the ureteric bud epithelial cells. Although morphologically similar to the epithelium in the renal pelvis and ureters, the urothelium of the urinary bladder and urethra is derived from the ventral urogenital sinus. The urogenital sinus is of endodermal origin 37, 38 and PAX8 has not been detected in this area at any embryonic stages, which is consistent with the lack of PAX8 expression in the urothelium and urothelial carcinomas of the urinary bladder. Whether the urothelial carcinomas of the ureter may express PAX8 needs further investigation in large numbers of tumors from this area.
In addition, PAX8 is expressed in the thyroid diverticulum in the early embryonic stage and is required for the formation and differentiation of the follicular cells. [39] [40] [41] Mutations of PAX8 cause congenital thyroid hypoplasia or absence of thyroid glands. [42] [43] [44] PAX8 is detected in the follicular cells of adult human thyroid gland and the follicular cellderived thyroid neoplasm. [45] [46] [47] During embryonic stages, PAX8 is also detected in Mü llerian ducts, the embryonic structures adjacent to the Wolffian ducts and the precursor tissues for the female genital tract. In males, the genital tracts derive from the remnant of the Wolffian duct and share a distant common embryonic origin as the kidney. The epithelial cells of female and male genital tracts are positive for PAX8. Mutations of PAX8 cause infertility in male and female mice because of the malformation and obstruction of the genital tracts. 48, 49 PAX8 is also detected in ovarian epithelial carcinomas 50 and is a useful differential marker from breast carcinomas. 51 Expression of PAX8 was described in tumors of other tissue origins; 29, 52, 53 however, it has not been substantiated by immunohistochemistry in recent publications. 29, 51 PAX8 was not detected in metastatic carcinomas from breast, colon, pancreas, or lung in body fluid (unpublished data). All these evidences support that PAX8 expression is limited to a few normal and neoplastic tissues in a celllineage-dependent manner and may be used as an additional immunohistochemical marker for renal epithelial tumors. However, its specificity and sensitivity in diagnostic application await further investigation.
